Innate Pharma SA Files 6-K Report
Ticker: IPHYF · Form: 6-K · Filed: Mar 19, 2024 · CIK: 1598599
| Field | Detail |
|---|---|
| Company | Innate Pharma SA (IPHYF) |
| Form Type | 6-K |
| Filed Date | Mar 19, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 6-K, foreign-private-issuer, sec-filing
TL;DR
Innate Pharma SA filed a 6-K, standard procedure for foreign issuers.
AI Summary
On March 19, 2024, Innate Pharma SA filed a Form 6-K. This report is for a foreign private issuer and is filed pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934. The company is based in Marseille, France, and its fiscal year ends on December 31st.
Why It Matters
This filing indicates Innate Pharma SA is a foreign private issuer, which has implications for its reporting obligations and compliance with US securities laws.
Risk Assessment
Risk Level: low — This is a routine filing for a foreign private issuer and does not contain new financial or operational information.
Key Numbers
- 001-39084 — SEC File Number (Identifies the company's filing with the SEC)
Key Players & Entities
- Innate Pharma SA (company) — Registrant
- March 19, 2024 (date) — Filing Date
- 117 Avenue de Luminy (address) — Principal Executive Office
- Marseille, France (location) — Company Location
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers required to be filed pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, typically to provide information that the registrant makes or is required to make public in its home country.
When was this Form 6-K filed?
This Form 6-K was filed on March 19, 2024.
Where is Innate Pharma SA headquartered?
Innate Pharma SA is headquartered in Marseille, France.
What is Innate Pharma SA's fiscal year end?
Innate Pharma SA's fiscal year ends on December 31st.
Does Innate Pharma SA file an annual report on Form 20-F?
Yes, the filing indicates that Innate Pharma SA files annual reports under cover of Form 20-F.
Filing Stats: 205 words · 1 min read · ~1 pages · Grade level 10.2 · Accepted 2024-03-19 06:33:07
Filing Documents
- a6k-iphx2402211.htm (6-K) — 9KB
- exhibit991-2402211.htm (EX-99.1) — 12KB
- 0001598599-24-000012.txt ( ) — 23KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. INNATE PHARMA S.A. Date March 19, 2024 By s HERVE BRAILLY Name Herv Brailly Title Chairman of the Executive Board and Chief Executive